drugset / Trial / NCT01549119
Phase I/IIa Dose-escalation Clinical Study of VAC-3S
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with undetectable viral loads.
Timeline
- Start
- 2012-02
- Primary completion
- 2013-02
- Completion
- 2014-12